Phase III Trial of Immunotherapy-Based Combination Therapy with or without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (Probe Trial)

Protocol No
SWOG-S1931-PROBE-TRIAL
Principal Investigator
Kathryn Bylow
Phase
III
Summary
The purpose of this study is to compare any good and bad effects of performing surgery to reduce the amount of cancer in the body. Your doctors have decided that you will benefit from receiving a combination drug treatment containing an immunotherapy drug. We wish to understand the effects of starting drug therapy followed by possible surgery and then more drug therapy. Surgery will remove your kidney tumor, and either your entire kidney or part of your kidney will be removed. We are doing this study because we want to find out if this approach is better or worse than the usual approach for kidney cancer. The usual approach is defined as care most people get for kidney cancer.
Description
Immunotherapy-Based Drug Combo w wo Surgery to Remove Kidney in Mets Kidney Cancer
Participating Institutions
Drexel Town Center
Froedtert Menomonee Falls Hospital
Froedtert West Bend Hospital
Froedtert Hospital
Status
OPEN TO ACCRUAL